Bay­er boost­ed as FDA OKs its PI3K drug Aliqopa for re­lapsed fol­lic­u­lar lym­phoma pa­tients

A lit­tle more than a year ago, Gilead ran in­to some se­ri­ous prob­lems when its PI3K can­cer pill Zy­delig was linked with a rash of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.